drugset

drugset / Trial / NCT04134273

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

NCT04134273 ↗

Phase 1 Completed 1260 enrolled Sun Pharmaceutical Industries, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is to evaluate the therapeutic equivalence and safety of Taro Product to RLD in the treatment of acne vulgaris.

Timeline

Start: 2019-03-20
Primary completion: 2019-09-17
Completion: 2019-10-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Clindamycin	Unknown	1 %	Topical

Indications